Table 3 Summary of clinical studies on allogeneic hematopoietic stem cell transplant (AHSCT) for patients with blast or accelerated phase myeloproliferative neoplasms (MPN-BP/AP) (References cited in the text).
From: Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm
Study | MPN type/Median age | Pre-AHSCT chemotherapy | Disease status at AHSCT | Donor type | Conditioning regimen | GvHD GRFS | Relapse rate | Overall survival | Predictors of inferior survival |
|---|---|---|---|---|---|---|---|---|---|
Orti et al. AJH 2023 N = 663 | MPN-BP 60 years | Intensive* 49% HMA 6% Ruxolitinib 3% Other 33% | CR 45% | Matched 65% MRD 28% MUD 35% MMUD 18% MMRD 9% | RIC 65% MAC 35% | 1-year GRFS 29% 3-year GRFS 18% | 3-year 48% 5-year 51% | 3- year 36% 5-year 32% | Absence of CR Performance score AHSCT 2005-2010 |
Kroger et al. BJH 2019 N = 422 | MPN-BP 59 years | - | CR 43% | MRD 36% MUD 64% | MAC 34% RIC 66% | Acute 26% Chronic 48% | 3-year 50% | 3- year 33% | Unrelated donor Graft source (PB) Absence of CR Older age Performance score CMV+ Unfavorable karyotype Ex-vivo T cell depletion |
Gupta et al. Blood Advances 2020 N = 177 | MPN-BP 59 years | Intensive 57% HMA 4% None 6% | CR 57% | MRD 31% MUD 47% MMUD 15% | MAC 52% RIC 48% | 5-year 66% | 5-year 18% | Adverse karyotype TP53 mutation Graft source (BM) | |
Cahu et al. BMT 2014 N = 60 | MPN-BP n = 43 MDS/MPN-BP n = 17 57 years | Intensive 78% HMA 5% None 12% | CR 43% | MRD 38% MUD 35% MMUD 27% | RIC 77% MAC 23% | 3-year 68% | 3-year 18% | Absence of CR Adverse karyotype | |
Lussana et al. Haematologica 2014 N = 57 | MPN-BP 56 years | None 11% | CR 39% | MRD 46% MUD 50% | MAC 40% RIC 60% | 53% | 3-year 28% | ||
Alchalby et al. BBMT 2014 N = 46 | MPN-BP 55 years | Intensive 91% | CR 24% | MRD 37% MUD 57% MMUD 4% | RIC 57% MAC 43% | Acute 50% Chronic 63% | 3-year 47% | 3-year 33% | Absence of CR |
Shah et al. BJH 2021 N = 43 | MPN-BP 59 years | Intensive 67% HMA 23% None 16% | CR 42% | MRD 40% MUD 60% | MAC 67% RIC 33% | Acute 46% Chronic 33% | 43% | 38% | AHSCT 2001-2009 |
Gagelmann et al. Blood Advances 2022 N = 35 | MPN-AP 58 years | None | AP | MRD 23% MUD 63% MMUD 14% | RIC 100% | 5-year 49% 5-year 31% | 5-year 65% | CALR/MPL unmutated RAS mutation Performance score Age ≥57 years | |
Kennedy et al. Blood 2013 N = 17 | MPN-BP 59 years | Intensive 94% | CR 59% | MRD 70% MUD 24% MMUD 6% | RIC 81% MAC 13% | Acute 77% Chronic 53% | 33% | 2-year 15% | Age > 60 years Performance score BM blasts ≥50% Albumin <3.2 g/dl |
Ruggiu et al. BBMT 2020 N = 16 | MPN-BP MDS-EB2 65 years | Intensive 42% HMA 40% | CR 69% | MRD 38% MUD 19% MMUD 19% Haplo 6% Cord 19% | MAC 52% RIC 48% | 2- year 34% | |||
Ciuera et al. BBMT 2010 N = 14 | MPN-BP 59 years | Intensive 93% | CR 43% | MRD 57% MUD 29% Mismatched 14% | RIC 64% MAC 29% | Acute 50% Chronic 36% | 29% | 2-year 49% |
